Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. Lancet Oncol. 2016;17(2):e81–6.
Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929–44.
Article CAS PubMed PubMed Central Google Scholar
Luchini C, Lawlor RT, Milella M, Scarpa A. Molecular tumor boards in clinical practice. Trends Cancer. 2020;6(9):738–44.
Wang C-Y, Wei L-Q, Niu H-Z, Gao W-Q, Wang T, Chen S-J. Agitation thrombolysis combined with catheter-directed thrombolysis for the treatment of non-cirrhotic acute portal vein thrombosis. World J Gastroenterol. 2018;24(39):4482.
Article PubMed PubMed Central Google Scholar
Aykan NF, Özatlı T. Objective response rate assessment in oncology: current situation and future expectations. World J Clin Oncol. 2020;11(2):53.
Article PubMed PubMed Central Google Scholar
Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J. 2009;15(5):386–94.
Article CAS PubMed Google Scholar
Delgado A, Guddati AK. Clinical endpoints in oncology-a primer. Am J cancer Res. 2021;11(4):1121.
PubMed PubMed Central Google Scholar
Dienstmann R, Garralda E, Aguilar S, Sala G, Viaplana C, Ruiz-Pace F et al. Evolving Landscape of molecular prescreening strategies for oncology early clinical trials. JCO Precis Oncol. 2020;4.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Article CAS PubMed Google Scholar
Schwartz LH, Litière S, De Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1—update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7.
Article PubMed PubMed Central Google Scholar
Feinberg BA, Zettler ME, Klink AJ, Lee CH, Gajra A, Kish JK. Comparison of solid tumor treatment response observed in clinical practice with response reported in clinical trials. JAMA Netw Open. 2021;4(2):e2036741–e.
Article PubMed PubMed Central Google Scholar
Paesmans M, Sculier J, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European lung cancer working party. Eur J Cancer. 1997;33(14):2326–32.
Article CAS PubMed Google Scholar
Goffin J, Baral S, Tu D, Nomikos D, Seymour L. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res. 2005;11(16):5928–34.
El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol. 2008;26(8):1346–54.
Walia A, Haslam A, Prasad V. FDA validation of surrogate endpoints in oncology: 2005–2022. J Cancer Policy. 2022;34:100364.
Shahnam A, Hitchen N, Nindra U, Manoharan S, Desai J, Tran B, et al. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: a meta-analysis across diverse tumour groups and contemporary therapies. Eur J Cancer. 2024;198:113503.
Li L, Pan Z. Progression-free survival and time to progression as real surrogate end points for overall survival in advanced breast cancer: a meta-analysis of 37 trials. Clin Breast Cancer. 2018;18(1):63–70.
Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009;4(3):311–7.
Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück H-J et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. 2008.
Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou S-HI, Pacheco JM, et al. Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387(2):120–31.
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1.
Article CAS PubMed Google Scholar
Heinrich K, Miller-Phillips L, Ziemann F, Hasselmann K, Rühlmann K, Flach M, et al. Lessons learned: the first consecutive 1000 patients of the CCCMunich(LMU) molecular tumor board. J Cancer Res Clin Oncol. 2023;149(5):1905–15.
Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1–Standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur J Cancer. 2016;62:138–45.
Article PubMed PubMed Central Google Scholar
Pannu HK, Bristow RE, Montz FJ, Fishman EK. Multidetector CT of peritoneal carcinomatosis from ovarian cancer. Radiographics. 2003;23(3):687–701.
D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808.
Article PubMed PubMed Central Google Scholar
Kok P-S, Yoon W-H, Lord S, Marschner I, Friedlander M, Lee CK. Tumor response end points as surrogates for overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis. JCO Precision Oncol. 2021;5:1151–9.
Feinberg BA, Bharmal M, Klink AJ, Nabhan C, Phatak H. Using response evaluation criteria in solid tumors in real-world evidence cancer research. Future Oncol. 2018;14(27):2841–8.
Article CAS PubMed Google Scholar
Charara RN, Kreidieh FY, Farhat RA, Al-Feghali KA, Khoury KE, Haydar A, et al. Practice and impact of multidisciplinary tumor boards on patient management: a prospective study. J Global Oncol. 2017;3(3):242–9.
Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? The lancet oncology. 2006;7(11):935–43.
Ruhstaller T, Roe H, Thürlimann B, Nicoll JJ. The multidisciplinary meeting: an indispensable aid to communication between different specialities. Eur J Cancer. 2006;42(15):2459–62.
Beets G, Sebag-Montefiore D, Andritsch E, Arnold D, Beishon M, Crul M, et al. ECCO essential requirements for quality cancer care: colorectal cancer. A critical review. Crit Rev Oncol/Hematol. 2017;110:81–93.
Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, et al. European society of endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2023;189(1):G1–42.
Andritsch E, Beishon M, Bielack S, Bonvalot S, Casali P, Crul M, et al. ECCO essential requirements for quality cancer care: soft tissue sarcoma in adults and bone sarcoma. A critical review. Crit Rev Oncol/Hematol. 2017;110:94–105.
Allum W, Lordick F, Alsina M, Andritsch E, Ba-Ssalamah A, Beishon M, et al. ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. Crit Rev Oncol/Hematol. 2018;122:179–93.
Brausi M, Hoskin P, Andritsch E, Banks I, Beishon M, Boyle H, et al. ECCO essential requirements for quality cancer care: prostate cancer. Crit Rev Oncol/Hematol. 2020;148:102861.
Comments (0)